Lonza licenses dual-payload ADC technology to Antharis for GI cancer programs - The Pharma Letter
Lonza licenses dual-payload ADC technology to Antharis for GI cancer programs The Pharma Letter
Lonza licenses dual-payload ADC technology to Antharis for GI cancer programs The Pharma Letter
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.